Age-related macular degeneration (AMD) is one of the leading causes of vision loss among adults over 65. This condition ...

The FDA approved Eylea HD for the treatment of macular edema following retinal vein occlusion, according to a press ...

The research team is now monitoring 12 more participants who received higher doses of 150,000 and 250,000 cells. If no safety ...

The US Food and Drug Administration (FDA) has approved aflibercept injection 8 mg (EYLEA HD) from Regeneron Pharmaceuticals ...

University of Minnesota Medical School researchers have shown that reducing chronic inflammation can significantly protect against age-related macular degeneration (AMD)-like pathology in preclinical ...

First and only FDA-approved treatment for RVO indicated for up to every 8-week dosing after an initial monthly dosing period Monthly dosing option in all approved indications provides greater dosing ...

Age-related macular degeneration (AMD) is one of the leading causes of vision loss among adults over 65. This condition affects the back of the eye where light is processed by ...

University of Minnesota Medical School researchers have shown that reducing chronic inflammation can significantly protect ...

People with severe vision loss have been able to read again, thanks to a tiny wireless chip implanted in one of their eyes ...

A wireless implant helped patients with severe macular degeneration regain usable vision. The results point toward a new ...

Secondary techniques are needed to address macular holes in patients with myopia, according to a speaker at OSN New York ...

The FDA has approved Eylea HD (aflibercept) 8 mg to treat patients with macular edema following retinal vein occlusion (RVO) with dosing of up to every 8 weeks after an initial monthly dosing period.